PPARA and metabolic dysfunction-associated steatohepatitis: A systematic review reported that PPAR agonists, such as pioglitazone and lanifibranor, and GLP-1RAs (mostly liraglutide and semaglutide) improved the individual histological features of MASH (steatosis, ballooning, lobular inflammation) or achieved resolution of MASH without a worsening of fibrosis.